| Private Placement / Financing Transactions
Eikon Therapeutics: The company raised $350.7 million of Series D venture funding from Foresite Capital, Lux Capital and The Column Group on February 26, 2025, putting the company’s pre-money valuation at $1.5 billion. General Catalyst, E15 VC, AME Cloud Ventures, Alexandria Venture Investments, UC Investments, StepStone Group, Soros Capital Management, and other undisclosed investors also participated in the round. The company is an operator of a drug discovery and development platform intended to offer a novel treatment for life-threatening diseases.
Enveda: The company raised $150 million of Series C venture funding in a deal led by FPV Ventures and Kinnevik on February 26, 2025, putting the company’s pre-money valuation at $490 million. Sanofi, Peakline Partners, Premji Invest, Baillie Gifford, True Ventures, Lux Capital, Henry Kravis, The Nature Conservancy, Dimension Capital Management and Lingotto also participated in the round. The company is a developer of a drug analysis platform designed to capitalize on the chemical diversity and evolutionary significance of natural samples.
OrganOx: The company received $142 million of development capital from HealthQuest Capital, BGF, Lauxera Capital Partners, Sofina, Soleus Capital, Longwall Ventures, Oxford Technology Management, Technikos, Oxford University Innovation, Avidity Partners and University of Oxford on February 24, 2025. The company is a developer and manufacturer of organ preservation and transplantation devices designed to reduce liver decay.
CoRegen: The company raised $30.8 million of venture funding from undisclosed investors on February 28, 2025. The company is a developer of a drug discovery platform intended to accelerate the development of new cancer treatments.
VarmX: The company raised EUR 15 million of venture funding from European Innovation Council Fund on February 26, 2025. The company is an operator of a biotech business developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.
Chimeron Bio: The company raised $13.7 million of venture funding from undisclosed investors on March 2, 2025. The company is a developer of self-amplifying mRNA vaccines intended to offer gene therapies and personalized medicines to patients.
Paradox Immunotherapeutics: The company raised $10 million of venture funding in a deal led by SymBiosis Capital Management on February 25, 2025. The company is an operator of a biotech business intended to develop front-line monoclonal antibody (mAb) treatment for protein misfolding diseases.
Vaxess Technologies: The company raised $8.4 million of venture funding from undisclosed investors on February 26, 2025. The company is a developer of novel therapies designed to help in oncology care and infectious diseases.
EarLens: The company raised $8 million of venture funding from undisclosed investors on February 28, 2025. The company is a developer of hearing aids.
iView Therapeutics: The company raised $7.7 million of Series A venture funding in a deal led by Chongqing Dian Petrochemical Medical Fund Management on February 24, 2025. Proxima Ventures and Hangzhou Jiurun Investment also participated in the round. The company is a developer of topical drugs designed for applications in ophthalmology, dermatology, and otolaryngology.
SIRPant Immunotherapeutics: The company raised $6.5 million of Series A venture funding from BioAdvance Captial and other undisclosed investors on February 25, 2025, putting the company’s pre-money valuation at $43.3 million. The company is a developer of cancer-specific immunotherapy designed for the treatment of solid tumors.
BIOHM Health: The company raised $4.5 million of Series B1 venture funding from undisclosed investors on February 26, 2025, putting the company’s pre-money valuation at $32.5 million. The company is a manufacturer of gut health products and personalized supplement kits.
Monument Therapeutics: The company raised GBP 2.8 million of venture funding in a deal led by Cambridge Angels and ACF Investors on February 25, 2025, putting the company’s pre-money valuation at GBP 7.3 million. O2h Ventures, Meltwind Advisory, SyndicateRoom, Manchester Tech Trust Angels, Wren Capital and The Forster Foundation also participated in the round. The company is a developer of novel drugs intended to treat serious diseases of the central nervous system.
Synlico: The company raised $3 million of venture funding through a combination of convertible debt and equity from undisclosed investors on February 25, 2025. The company is a developer of an AI platform that predicts the effects of gene interventions and cell behaviors in patients, aiding in the design of effective cell therapies.
Atrix AI: The company raised an undisclosed amount of venture funding from Twine Ventures in March 2025. The company is a developer of a medical insights platform designed to transform raw data into actionable insights to improve patient outcomes and clinical opportunities.
Creasallis: The company raised an undisclosed amount of venture funding from ZAKA VC in March 2025. The company is a developer of antibody therapeutics designed to improve solid tumor penetration.
Omniscope: The company raised an undisclosed amount of venture funding from Barca Innovation Hub and Buenavista Equity Partners on February 25, 2025. The company is a developer of an AI-based platform intended to decode the immune system and enable cellular therapeutic development.
Presymptom Health: The company is in the process of raising Series A venture funding on February 28, 2025. The company is an operator of a medtech business focused on developing pre-symptomatic diagnostic tests to detect illnesses.
QDI systems: The company raised venture funding from an undisclosed investors on February 24, 2025. The company is a developer of medical imaging devices using quantum dot technology.
|
